Novel Trispecific CD19.t-haNK TM Natural Killer Cell Therapy Engineered for Enhanced Tumor Homing for B Cell Lymphoma CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 3, 2018-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the
NantKwest to Participate at Upcoming Investment Conferences CULVER CITY, CALIFORNIA-(BUSINESS WIRE), November 12, 2018 NantKwest (Nasdaq:NK), a leading clinical-stage, natural killer cell based therapeutics company, today announced that the company will be participating at a number of investment
Combination in 30 Patients with Advanced Metastatic Cancer Refractory to Multiple Previous Therapies Zero Incidence of Cytokine Release Syndrome in Any of the 300 Doses in 30 Patients All Patients Received NK Cell Infusion and Novel Cancer Memory Vaccine Combination as Outpatients with No
Update on Off-The-Shelf CD16 Targeted NK Cell (haNK) and NANT Cancer Vaccine Program Including Interim Data Analysis for Pancreatic Cancer, Triple Negative Breast Cancer & Head and Neck Cancer Trials CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 5, 2018-- NantKwest (NASDAQ: NK), a leading,
CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 2, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at the upcoming Cantor Global Healthcare Conference on Tuesday, October 2 nd in New York City
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 19, 2018-- NantKwest, Inc. (Nasdaq: NK) today announced the elevation of Sonja Nelson , chief accounting officer for the company, to the role of Chief Financial Officer (CFO). This press release features multimedia.
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 5, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that Dr. Patrick Soon-Shiong , Chairman & CEO of NantKwest , will be presenting and conducting one-on-one meetings at the upcoming
CULVER CITY, Calif. --(BUSINESS WIRE)--Apr. 23, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at two science and medicine conferences in the months of April and May 2018 .
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 13, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the
CULVER CITY, Calif. --(BUSINESS WIRE)--Mar. 13, 2018-- NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell-based therapeutics company, today announced that the company will be presenting and conducting one-on-one meetings at a number of investment and healthcare conferences in the
